| Volume: | 8,518,646 |
|---|---|
| Day's Low: | $59.57 |
| 52-wk Low: | $46.25 |
| Previous Close: | $59.98 |
| Dividend: | $0.49 |
| Market Cap: | 166,373,700 |
| Avg Volume: | 10,974,000 |
|---|---|
| Day's High: | $60.34 |
| 52-wk High: | $63.01 |
| Open Price: | $59.94 |
| Yield: | 3.25% |
| P/E (Forward): | 13.17 |
| 10:53 AM | 11/6/2009 | 2ndUPDATE: Smith & Nephew 3Q Net +73%;US Hip, Knee Sales Lag |
| 7:17 AM | 11/6/2009 | Smith & Nephew 3Q Net Profit +73%; Signs Market Stabilizing |
| 7:17 AM | 11/6/2009 | UPDATE: Smith & Nephew 3Q Net +73%; US Hip, Knee Sales Lag |
| 4:27 PM | 11/4/2009 | Johnson & Johnson Stops Making Evolence, A Facial Filler |
| 12:14 PM | 11/4/2009 | 2nd UPDATE: Merck Sees High-Single-Digit EPS Growth Through '13 |
| 11:03 AM | 11/4/2009 | UPDATE: Merck Sees High-Single-Digit EPS Growth Through 2013 |
| 6:17 PM | 11/3/2009 | 3rd UPDATE: DOJ: Omnicare, Teva Unit To Pay In Kickbacks Case |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.20 | 1.17 | 2.56 |
| EPS, GAAP | 1.20 | 1.17 | 2.56 |
| Consensus Estimate | 1.13 | 1.11 | 1.80 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 4.55 | 4.55 | 0.00 |
| EPS, GAAP | 4.58 | 4.42 | 3.62 |
| Consensus Estimate | 4.38 | NA | NA |
| JNJ | Industry Average | |
| P/E (TTM) | 13.17 | 18.40 |
| P/E (Forward) | 13.17 | -4.30 |
| PEG Ratio | 1.66 | -0.28 |
| Price/Sales | 2.78 | 2.94 |
| Beta | 0.55 | 0.60 |